Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.64 |
| ▸ | EGFR | P00533 | 10/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070414 | 1.00 | DDB1 (0.64) | DDB1CRBNEGFR | |
| SCHEMBL20845731 | 1.00 | DDB1 (0.64) | DDB1CRBNEGFR | |
| SCHEMBL21070334 | 1.00 | DDB1 (0.64) | DDB1CRBNEGFR | |
| SCHEMBL21069722 | 0.98 | DDB1 (0.62) | DDB1CRBNEGFR | |
| SCHEMBL21070770 | 0.95 | DDB1 (0.58) | DDB1CRBNEGFR | |
| SCHEMBL21070170 | 0.95 | DDB1 (0.57) | DDB1CRBNEGFR | |
| SCHEMBL20840290 | 0.90 | CRBN (0.51) | DDB1CRBNEGFR | |
| SCHEMBL21069221 | 0.90 | DDB1 (0.53) | DDB1CRBN | |
| SCHEMBL21106789 | 0.90 | CRBN (0.52) | DDB1CRBN | |
| SCHEMBL26100394 | 0.90 | DDB1 (0.50) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12540127-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358948-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885EGFR 114/4885 |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885EGFR 114/4885 |
| US-12540127-B2 | CRBN ligands and uses thereof | CRBN, NR2C2, NR2E3 | DDB1 1571/4885CRBN 1/4885EGFR 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.